埃利奥斯:一项多中心的分子分析研究,对EGFR突变高级非小细胞肺癌患者进行了第一线奥西默蒂尼布治疗
Zofia Piotrowska1, Myung-Ju Ahn2, Pei Jye Voon3
1Massachusetts General Hospital Boston, Massachusetts United States.
Cancer discovery
|March 6, 2026
概括
晚期EGFR突变非小细胞肺癌 (NSCLC) 对奥西默提尼布的获得性耐药性涉及MET放大和EGFR C797S等常见变异. 组织和血NGS揭示了多样化的抗药机制,需要广泛的治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 第一线 osimertinib 是对EGFR突变的高级非小细胞肺癌 (NSCLC) 的标准治疗.
- 了解获得性耐药机制对于改善患者的治疗结果至关重要.
研究的目的:
- 为了描述EGFR突变高级NSCLC中对一线 osimertinib的获得性耐药机制.
- 为了比较治疗前和进展后的瘤活检.
主要方法:
- 一项前性研究 (ELIOS,NCT03239340) 涉及154名患有EGFR突变性晚期NSCLC的患者.
- 在配对的组织活检 (n=52) 和匹配的组织/血样本 (n=51) 上进行下一代测序 (NGS).
- 蛋白质基因组分析 (n=32基线,n=18后进展).
主要成果:
- 常见的获得性改变包括MET放大 (17%),CDKN2A/CDKN2B删除 (15%),MTAP删除 (13%) 和EGFR C797S (13%).
- 在基线和进展后,TROP2表达在基因变异无关的情况下都很高.
- 82%具有匹配后进展样本的患者通过NGS显示了耐药性改变.
结论:
- 组织活检在接受向治疗的NSCLC患者中具有挑战性,以获得后进展.
- 获得性耐药性机制是异质的,强调了需要广泛的治疗策略.
- 已经证明了组织和血NGS在识别耐药机制方面的互补作用.
相关概念视频
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...